The emergence of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) as a pillar of guideline-directed medical therapy in heart failure (HF) management is due to its associated morbidity and mortality benefits [1]. This evidence concerns the gene SLC5A2 and heart failure.